Edgewise Therapeutics doses first patient in Phase 2 Equinox-HFpEF trial of EDG-15400
EWTX•Edgewise Therapeutics dosed the first patient in its Phase 2 Equinox-HFpEF trial of EDG-15400.
1. Trial begins dosing
Edgewise Therapeutics said it dosed the first patient in its Phase 2 Equinox-HFpEF trial of EDG-15400.
